title: Bortezomib combined with thalidomide and dexamethasone is effective for patient with crystal-storing histiocytosis associated with monoclonal gammopathy of undermined significance.
authors.forename: Xiaoxia
authors.initials: X
authors.lastname: Hu
authors.forename: Jiaxiang
authors.initials: J
authors.lastname: Liu
authors.forename: Chenguang
authors.initials: C
authors.lastname: Bai
authors.forename: Jianmin
authors.initials: J
authors.lastname: Wang
authors.forename: Xianmin
authors.initials: X
authors.lastname: Song
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D001897:Boronic Acids / Q000008:administration & dosage*; D000069286:Bortezomib; D003907:Dexamethasone / Q000008:administration & dosage*; D005260:Female; D015614:Histiocytosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D006801:Humans; D010265:Paraproteinemias / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D011719:Pyrazines / Q000008:administration & dosage*; D013792:Thalidomide / Q000008:administration & dosage*
chemical_list: D020533:Angiogenesis Inhibitors; D018931:Antineoplastic Agents, Hormonal; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone